Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification
Sai-Hong Ignatius Ou, Eunice L Kwak, Christina Siwak-Tapp, Joni Dy, Kristin Bergethon, Jeffrey W Clark, D Ross Camidge, Benjamin J Solomon, Robert G Maki, Yung-Jue Bang, Dong-Wan Kim, James Christensen, Weiwei Tan, Keith D Wilner, Ravi Salgia, A John Iafrate, Sai-Hong Ignatius Ou, Eunice L Kwak, Christina Siwak-Tapp, Joni Dy, Kristin Bergethon, Jeffrey W Clark, D Ross Camidge, Benjamin J Solomon, Robert G Maki, Yung-Jue Bang, Dong-Wan Kim, James Christensen, Weiwei Tan, Keith D Wilner, Ravi Salgia, A John Iafrate
Abstract
Crizotinib is a dual MET and ALK inhibitor. Currently, clinical development of crizotinib is focused primarily on ALK rearranged non-small cell lung cancer (NSCLC). Here we report an NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.
Trial registration: ClinicalTrials.gov NCT00585195.
Source: PubMed